Medical Breakthroughs of 2026: The Biggest Advances So Far

Updated October 1, 2026 · 13 min read

Medical progress usually arrives quietly: an approval letter, a journal paper, a certificate from the World Health Organization. Here are the most significant advances of the year so far, grouped by area, with a plain statement of where each one stands.

Every item below was checked against a primary or authoritative source, such as the FDA, WHO, a peer-reviewed journal, or a university press office, and every figure is quoted from that source. A trial result is not the same as an approved treatment, so each item says which it is. For good news beyond medicine, see our roundup of good news stories of 2026.

Jump to a section:

• Cancer
• Genetic and rare diseases
• Infectious disease and global health
• Heart, brain, and chronic disease
• AI and diagnostics
• Other notable advances

Cancer

Pancreatic cancer and melanoma both saw meaningful news this year, along with fresh evidence that a vaccine given to children is preventing cancer deaths in young adults.

A first-in-class targeted pill improved survival in metastatic pancreatic cancer

The FDA approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. It is a once-daily tablet that targets multiple forms of RAS, a protein that drives tumor growth in most patients with this cancer. In a randomized trial of 500 adults with previously treated metastatic disease, median overall survival was 13.2 months with Rasonque compared with 6.7 months with standard chemotherapy.

Status: approved by the FDA. Source: US Food and Drug Administration, August 2026

A personalized mRNA cancer vaccine slowed the return of melanoma in a phase 3 trial

Merck and Moderna reported that intismeran, a personalized mRNA vaccine given together with the immunotherapy Keytruda, slowed the return of melanoma and its spread to other parts of the body in patients whose melanoma had been surgically removed. STAT described it as the first randomized phase 3 trial aimed at definitively proving the benefit of this kind of personalized neoantigen vaccine. Detailed data were not released with the announcement, and the vaccine is not approved.

Status: phase 3 trial results, announced by the companies. Source: STAT, August 2026

Early pancreatic cancer vaccine results held up after several years

Memorial Sloan Kettering researchers presented long-term follow-up from an early trial of autogene cevumeran, a personalized mRNA vaccine given after surgery for pancreatic cancer. In 8 of the 16 patients, the vaccine activated immune cells that recognize the tumor, and 7 of those 8 were still alive 4 to 6 years after surgery. The study was small, and a larger global phase 2 trial is now testing the vaccine.

Status: early-stage trial, results presented at the American Association for Cancer Research annual meeting. Source: Memorial Sloan Kettering Cancer Center, April 2026

A blood-test-guided breast cancer treatment was approved

The FDA granted accelerated approval to camizestrant, sold as Etcamah, for HR-positive, HER2-negative advanced breast cancer with an ESR1 mutation that appears during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. Switching to Etcamah with a CDK4/6 inhibitor gave a median progression-free survival of 16 months, compared with 9.2 months for staying on an aromatase inhibitor with a CDK4/6 inhibitor. The FDA called it the first approval of a cancer therapy guided by detecting a resistance mutation in circulating tumor DNA.

Status: accelerated approval by the FDA. Source: US Food and Drug Administration, September 2026

No cervical cancer deaths among women aged 20 to 24 in England after HPV vaccination

A study published in The Lancet found that, for the first time, no women aged 20 to 24 in England died of cervical cancer between 2020 and 2024, when vaccine coverage in that age group was about 90%. Researchers at Queen Mary University of London estimate the HPV vaccine has prevented around 200 cervical cancer deaths in England so far, and say uptake remains below where it should be, especially in more deprived areas.

Status: published study. Source: Queen Mary University of London, June 2026

Genetic and rare diseases

Gene therapy and gene editing had a strong year, and several rare diseases that had no approved treatment at all now have one.

The first gene therapy for a genetic form of hearing loss was approved

The FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha) for severe to profound hearing loss caused by variants in the OTOF gene. It is given as a single dose per ear, delivered surgically into the cochlea. In the trial of 24 children aged 10 months to 16 years, 20 were evaluated for effectiveness, and 80% of them experienced improved hearing. Continued approval may depend on further evidence about how long the improvement lasts and its effect on speech development.

Status: accelerated approval by the FDA. Source: US Food and Drug Administration, April 2026

The first gene therapy for Sanfilippo syndrome type A was approved

The FDA approved Fayuvi (rebisufligene etisparvovec-hopf) for children with Sanfilippo syndrome type A, also called MPS IIIA, a rare inherited disease in which children who develop normally in their earliest years then regress. It is a one-time intravenous gene therapy that delivers a working copy of the SGSH gene. In a study of children aged 2 to 5, treated children maintained or improved cognitive function compared with an untreated historical control group. The FDA noted the disease had no approved treatment until now.

Status: approved by the FDA. Source: US Food and Drug Administration, September 2026

A one-time sickle cell gene therapy was extended to children as young as 2

The FDA expanded the approval of Casgevy (exagamglogene autotemcel) from patients aged 12 and older to those aged 2 and older with sickle cell disease and recurrent vaso-occlusive crises, or with transfusion-dependent beta thalassemia. In a trial of children aged 5 to 11 with sickle cell disease, all eight who could be evaluated went at least 12 consecutive months without a severe vaso-occlusive crisis. Eight of nine evaluable children with beta thalassemia stopped needing transfusions for at least 12 consecutive months.

Status: expanded approval by the FDA. Source: US Food and Drug Administration, July 2026

A single CRISPR treatment cut hereditary angioedema attacks by 87% in a phase 3 trial

The New England Journal of Medicine published phase 3 results for lonvoguran ziclumeran, a CRISPR gene editing treatment given once by infusion that edits genes inside the body. Among 80 patients with hereditary angioedema, which causes recurrent and sometimes life-threatening swelling attacks, the monthly attack rate from week 5 to week 28 was 0.26 with the treatment and 2.10 with placebo, a relative reduction of 87%. No serious adverse events were reported in the treated group. The treatment is still investigational.

Status: phase 3 trial results, published study. Source: New England Journal of Medicine, via PubMed, June 2026

The first treatment for Menkes disease was approved

The FDA approved Zycubo (copper histidinate) injection, the first treatment for children with Menkes disease, a rare genetic disorder that stops the body from absorbing copper properly. Children who began treatment within four weeks of birth had a 78% reduction in the risk of death compared with untreated patients, and nearly half of early-treated patients survived beyond six years. The approval was based on two open-label trials with 66 treated and 17 untreated children.

Status: approved by the FDA. Source: US Food and Drug Administration, January 2026

The first drug for Alexander disease was approved

The FDA approved Zanvastro (zilganersen) injection for children and adults with Alexander disease, a rare genetic disease of the brain that previously had no approved treatment. In the main randomized study of 49 patients aged 2 and older, patients aged 5 and older with walking difficulties had significantly better walking speed at 61 weeks than those who received no treatment.

Status: approved by the FDA. Source: US Food and Drug Administration, September 2026

Infectious disease and global health

Disease elimination is slow, patient work, and 2026 has been one of its better years. As of September, WHO counted 65 countries that have eliminated at least one neglected tropical disease.

Chile became the first country in the Americas verified as free of leprosy

WHO verified that Chile has eliminated leprosy, making it the first country in the Americas and the second in the world, after Jordan, to reach that milestone. Chile's last locally acquired case was detected in 1993, and multidrug therapy has been supplied free of charge since 1995.

Status: verified by WHO. Source: World Health Organization, March 2026

Three more places stopped HIV passing from mothers to babies

WHO certified Denmark in February as the first country in the European Union to eliminate mother-to-child transmission of HIV and syphilis. The Bahamas followed in April for HIV, after meeting targets that include a transmission rate below 2% and at least 95% coverage of antenatal care, HIV testing, and treatment for pregnant women. In June, WHO and PAHO certified the Turks and Caicos Islands for eliminating mother-to-child transmission of HIV and hepatitis B.

Status: certified by WHO. Sources: Denmark, February 2026; the Bahamas, April 2026; Turks and Caicos, June 2026 (all World Health Organization)

Trachoma was eliminated in Libya, Tunisia, and Timor-Leste

WHO validated three countries this year as having eliminated trachoma, the infectious eye disease that can cause blindness, as a public health problem. Libya became the 28th country to do so in February, Tunisia the 31st in May, and Timor-Leste the 33rd in September. With Timor-Leste, trachoma is now eliminated as a public health problem across WHO's entire South-East Asia Region.

Status: validated by WHO. Sources: Libya, February 2026; Tunisia, May 2026; Timor-Leste, September 2026 (all World Health Organization)

Bhutan eliminated dog-transmitted human rabies

WHO validated Bhutan as the first country in its South-East Asia Region to eliminate dog-transmitted human rabies as a public health problem. Bhutan has recorded no such deaths since June 2023, after mass dog vaccination, joint human and animal surveillance, and free post-exposure treatment in all 20 districts.

Status: validated by WHO. Source: World Health Organization, September 2026

An mRNA flu vaccine was approved for adults 50 and older

The FDA approved mFlusiva, Moderna's seasonal flu vaccine made with mRNA technology, for people aged 50 and older. In a phase 3 trial of 40,805 adults in 11 countries, it showed a relative vaccine efficacy of 26.6% against a standard-dose flu vaccine, meaning fewer confirmed flu illnesses than with the standard shot. Approval is traditional for ages 50 to 64 and accelerated for 65 and older, where the FDA requires a confirmatory efficacy study.

Status: approved by the FDA. Sources: US Food and Drug Administration product page and FDA review summary, August 2026

The first US treatment for chronic hepatitis delta was approved

The FDA granted accelerated approval to Hepcludex (bulevirtide-gmod), the first treatment for chronic hepatitis delta virus infection in the US, for adults without cirrhosis or with compensated cirrhosis. In a phase 3 trial, the combined response at week 48 was 48% with Hepcludex compared with 2% in the delayed treatment group, and undetectable virus levels rose to 50% by week 144.

Status: accelerated approval by the FDA. Source: US Food and Drug Administration, May 2026

Heart, brain, and chronic disease

Several common conditions gained new kinds of medicine this year, including pills for problems that previously needed injections.

The first cholesterol-lowering PCSK9 inhibitor in pill form was approved

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with high cholesterol, including those with an inherited form called heterozygous familial hypercholesterolemia. In two trials with 3,207 participants already taking statins, it reduced LDL cholesterol at week 24 by an average of 56% and 59% compared with placebo. Previously approved medicines in this class are injections.

Status: approved by the FDA. Source: US Food and Drug Administration, July 2026

A new type of blood pressure medicine was approved

The FDA approved Baxfendy (baxdrostat), an aldosterone synthase inhibitor, for adults whose high blood pressure is not adequately controlled on other medicines, taken alongside them. In the BaxHTN trial of 794 patients, the 2 mg dose lowered systolic blood pressure by 9.8 mmHg more than placebo after 12 weeks. The label asks doctors to monitor potassium and sodium levels.

Status: approved by the FDA. Sources: FDA prescribing information and FDA novel drug approvals for 2026, May 2026

A once-daily GLP-1 tablet for weight loss was approved in the US and UK

The FDA approved Foundayo (orforglipron), a once-daily GLP-1 tablet, for adults with obesity, or overweight with at least one weight-related condition, alongside diet and exercise. The FDA approved it 50 days after filing, which it called the fastest approval of a new molecular entity since 2002. In August, the UK's MHRA became the first regulator in Europe to authorise it, for weight management and type 2 diabetes, though it is not yet available on the NHS.

Status: approved by the FDA and authorised in the UK. Sources: US Food and Drug Administration, April 2026; MHRA, August 2026

The first narcolepsy drug to target its underlying cause was approved

The FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1, a lifelong sleep disorder caused by the loss of brain cells that produce orexin. The FDA said it is the first medicine approved to address the full range of symptoms and the first to directly target the loss of orexin signaling. In two studies with 273 adults, patients reported substantially less daytime sleepiness and a significant reduction in cataplexy episodes.

Status: approved by the FDA. Source: US Food and Drug Administration, August 2026

AI and diagnostics

The most useful AI news in medicine this year came from careful trials rather than product launches.

AI found hidden heart disease in a routine ECG in under two seconds

Research led by Imperial College London and funded by the British Heart Foundation, presented at the European Society of Cardiology Congress, showed an AI tool could identify up to 81% of patients with heart failure from a standard ECG, and up to 90% of a common heart valve disease, aortic stenosis, in one patient group. It was developed using 10.6 million ECGs and is now being trialled with 590 NHS patients in London and Bristol.

Status: research results, NHS trial under way. Source: British Heart Foundation, September 2026

AI-supported breast screening found more cancers in a trial of over 100,000 women

Final results from the Swedish MASAI trial, published in The Lancet, compared AI-supported mammography screening with standard double reading by radiologists in 105,934 women. Sensitivity was higher with AI support, 80.5% compared with 73.8%, with the same specificity of 98.5%. The rate of cancers diagnosed between screenings was non-inferior, with fewer invasive interval cancers (75 compared with 89), and the AI also reduced radiologists' reading workload.

Status: published randomized trial. Source: The Lancet, via PubMed, January 2026

Other notable advances

A pig kidney kept a man off dialysis for 271 days until he received a human kidney

A paper in The Lancet described Tim Andrews, who received a genetically edited pig kidney in January 2025 at age 66 and lived with it for 271 days. In January 2026 he received a donated human kidney, which had immediate graft function. Harvard Medical School says it is the longest dialysis-free survival after a pig kidney transplant in a living person, and the first transition from a pig kidney to a human one.

Status: published report on one patient. Source: Harvard Medical School, September 2026

What "approved" and "trial results" mean

An FDA approval means the agency has decided a treatment's benefits outweigh its risks for a specific group of patients in the United States. An accelerated approval is granted earlier, based on evidence reasonably likely to predict a benefit, and the company must usually confirm that benefit in further studies. Phase 3 trial results are the last major step before a company asks regulators for approval, so a positive result is encouraging but the treatment is not yet available outside trials. An early-stage trial involves a small number of people and is mainly about safety and first signs that something works. WHO validations, verifications, and certifications confirm that a country has met agreed targets for eliminating a disease.

How we chose these advances

We looked for developments that are significant beyond a single hospital: first-ever treatments, first-in-class medicines, large or rigorous trials, and disease eliminations confirmed by WHO. Each item had to be announced or published between January 1 and September 30, 2026, and each number is taken from the linked source. We left out results we could not confirm at a primary or authoritative source. Medical progress is uneven, and many people still lack access to approved treatments, which we cover more broadly in is the world getting better. For lighter, everyday stories, try this week's good news or good news today.

Frequently asked questions